Pharmaceutical - Antibiotics and Infectious diseases, Pharmaceutical

Filter

Popular Filters

1 to 25 of 211 results

New study identifies potential alternatives to Gilead’s Sovaldi

New study identifies potential alternatives to Gilead’s Sovaldi

29-07-2014

There are multiple hepatitis treatments in development that may serve as potential alternatives to Gilead…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbdaclatasvirGilead SciencesGlobalHepatitis C treatmentMarkets & MarketingmericitabinePharmaceuticalRocheSovaldi

New Zealand to fund Norgine’s Xifaxan for hepatic encephalopathy

New Zealand to fund Norgine’s Xifaxan for hepatic encephalopathy

15-07-2014

New Zealand Pharmaceutical Management Agency PHARMAC has awarded a tender to Netherlands-headquartered…

Antibiotics and Infectious diseasesFinancialHealthcareNew ZealandNorginePharmaceuticalXifaxan

Astellas details pipeline progress at R&D meeting

Astellas details pipeline progress at R&D meeting

11-07-2014

Japanese drug major Astellas Pharmaceuticals outlined its research framework at its R&D meeting held…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesAstellas PharmaBetmigaisavuconazoleJapanNephrology and HepatologyOncologyPharmaceuticalroxadustatXtandi

Research shows OPAT drugs should be first used on inpatients to penetrate the market

Research shows OPAT drugs should be first used on inpatients to penetrate the market

11-07-2014

While more than three quarters of surveyed infectious disease specialists are willing to prescribe Durata’s…

AntibioticsAntibiotics and Infectious diseasesDalvanceDecision Resources GrouporitavancinOritavancinPharmaceuticalResearch

Astellas submits NDA for isavuconazole to treat deadly fungal infections

Astellas submits NDA for isavuconazole to treat deadly fungal infections

10-07-2014

Japanese drug major Astellas Pharma has submitted a New Drug Application to the US Food and Drug Administration,…

Antibiotics and Infectious diseasesAntifungal therapiesAspergillosisAstellas PharmaBiologyFungal diseasesImmunologicalsInvasive aspergillosisisavuconazoleJapanMycologyPharmaceuticalRegulationZygomycosis

UK Ministers “must stop unnecessary use of antibiotics”

UK Ministers “must stop unnecessary use of antibiotics”

07-07-2014

A wide-raging report published today by the UK House of Commons Science and Technology Select Committee…

Antibiotics and Infectious diseasesHealthcarePharmaceuticalPoliticsResearchUK

GlobalData says UK fears over antibiotic resistance is

GlobalData says UK fears over antibiotic resistance is "valid conclusion"

04-07-2014

Earlier this week, UK Prime Minister David Cameron revealed the formation of an independent review panel…

Antibiotics and Infectious diseasesEuropePharmaceuticalResearchUSA

UK launches fresh fight against antimicrobial resistance

UK launches fresh fight against antimicrobial resistance

02-07-2014

The UK prime minister David Cameron has said he wants Britain to lead the way in the battle against antimicrobial…

Antibiotics and Infectious diseasesHealthcarePharmaceuticalUK

Transcept and Paratek join forces in reverse takeover

Transcept and Paratek join forces in reverse takeover

01-07-2014

US pharma company Transcept Pharmaceuticals and privately-held biopharmaceutical company Paratek Pharmaceuticals…

Antibiotics and Infectious diseasesMergers & AcquisitionsParatek PharmaceuticalsPharmaceuticalTranscept PharmaUSA

FDA calls for additional Ph III study for Basilea’s ceftobiprole

FDA calls for additional Ph III study for Basilea’s ceftobiprole

26-06-2014

Swiss drugmaker Basilea Pharmaceutica saw its shares drop as much as 12% yesterday, after it revealed…

Antibiotics and Infectious diseasesBacteriaBasilea PharmaceuticaceftobiproleHealth Medical PharmaHealth Medical PharmaisavuconazoleMedicinePharmaceuticalRegulationTreatment of pneumoniaUSA

BioAlliance Pharma signs deal with EMS for Sitavig in Brazil

BioAlliance Pharma signs deal with EMS for Sitavig in Brazil

26-06-2014

French oncology specialist BioAlliance Pharma SA has announced a license agreement for Sitavig (acyclovir…

Antibiotics and Infectious diseasesBioAlliance PharmaBrazilLicensingPharmaceuticalSitavig

Cubist’s Sivextro gets FDA approval for serious skin infections

Cubist’s Sivextro gets FDA approval for serious skin infections

22-06-2014

The US Food and Drug Administration has approved Cubist Pharmaceuticals’ Sivextro (tedizolid phosphate)…

Antibiotics and Infectious diseasesCubist PharmaceuticalsPharmaceuticalRegulationSivextroUSA

FDA accepts Cubist’s ceftolozane/tazobactam NDA with Priority Review

FDA accepts Cubist’s ceftolozane/tazobactam NDA with Priority Review

20-06-2014

The US Food and Drug Administration has accepted Cubist Pharmaceuticals’ New Drug Application for its…

Antibiotics and Infectious diseasesceftolozaneCubist PharmaceuticalsPharmaceuticalRegulationtazobactamUSA

UK’s Summit sets up operations in the USA

UK’s Summit sets up operations in the USA

17-06-2014

UK drug discovery firm Summit, which is focused on therapies for Duchenne muscular dystrophy and Clostridium…

Antibiotics and Infectious diseasesBoardroomManagementPharmaceuticalRare diseasesResearchSummit PharmaceuticalsUSA

Drug pricing power led by hepatitis C, diabetes and cancer

Drug pricing power led by hepatitis C, diabetes and cancer

13-06-2014

Hepatitis C, diabetes and cancer are sustaining high pricing power through innovation according to Morningstar's…

AbbVieAntibiotics and Infectious diseasesBiogen IdecCopaxoneDiabetesGenericsGilead SciencesMerck & CoOncologyPharmaceuticalPricingTecfideraTeva Pharmaceutical IndustriesUSA

Positive Ph III results with Cubist’s Sivextro in ABSSSI

Positive Ph III results with Cubist’s Sivextro in ABSSSI

06-06-2014

USA-based Cubist Pharmaceutical saw its share rise 3.1% to $70.80 in morning trading Friday, after the…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDermatologicalsPharmaceuticalResearchSivextro

Evotec to acquire Euprotec to establish an anti-infectives platform

Evotec to acquire Euprotec to establish an anti-infectives platform

29-05-2014

Germany’s Evotec says it has acquired all the shares in Euprotec Ltd, a UK-based specialist contract…

Anti-infective drug discovery servicesAntibiotics and Infectious diseasesBusiness FinanceDiseaseEvotecHealth Medical PharmaMergers & AcquisitionsPharmaceuticalRecognised leader

FDA approves Durata’s Dalvance to treat skin infections

26-05-2014

The US Food and Drug Administration last Friday approved Durata Therapeutics’ Dalvance (dalbavancin),…

Antibiotics and Infectious diseasesDalvanceDurata TherapeuticsPharmaceuticalRegulationUSA

New data shows Astellas’ fidaxomicin is effective as first-line treatment for Clostridium difficile infection

New data shows Astellas’ fidaxomicin is effective as first-line treatment for Clostridium difficile infection

14-05-2014

The European subsidiary of Japanese drug major Astellas Pharma has released data demonstrating that fidaxomicin…

Antibiotics and Infectious diseasesAstellas PharmaBacteriaDifficile infectionEuropefidaxomicinHealth Medical PharmaMedicineMicrobiologyPharmaceuticalResearch

Antibiotic crisis needs united global response, say UK experts

12-05-2014

Growing resistance to antibiotics and other drugs demands a coordinated global response on the same scale…

Antibiotics and Infectious diseasesGlobalHealthcarePharmaceuticalResearch

Antibiotic resistance is a serious public health threat according to WHO global report

Antibiotic resistance is a serious public health threat according to WHO global report

01-05-2014

Resistance of antibiotics is a serious threat happening now around the world, according to The World…

Antibiotics and Infectious diseasesGlobalHealthcarePharmaceutical

Otsuka wins EU approval for Deltyba in MDR-TB

30-04-2014

Japanese drugmaker Otsuka Pharmaceutical says that the European Commission has granted a marketing authorization…

Antibiotics and Infectious diseasesDeltybaEuropeOtsukaPharmaceuticalRegulation

Astellas settles with US DoJ over Mycamine marketing

Astellas settles with US DoJ over Mycamine marketing

17-04-2014

The US subsidiary of Japanese drug major Astellas Pharma will pay $7.3 million to resolve allegations…

Antibiotics and Infectious diseasesAstellas PharmaLegalMarkets & MarketingMycamineNorth AmericaPharmaceuticalUSA

Joint purchasing of vaccines and medicines becomes a reality in the EU

Joint purchasing of vaccines and medicines becomes a reality in the EU

10-04-2014

The European Commission today approved a Joint Procurement Agreement, which will enable all European…

Antibiotics and Infectious diseasesEuropeFinancialMarkets & MarketingPharmaceuticalVaccines

1 to 25 of 211 results

Back to top